SK Biopharmaceuticals (326030) Q3 2026 earnings summary

Executive summary

• Q3 revenue reached KRW 258.4B, up 34.8% YoY; operating profit was a record KRW 116.3B, up 65.9% YoY.

• XCOPRI Q3 sales were $156.8M; full-year sales were expected at the upper end of the $550M–$580M guidance range.

• Cumulative operating profit reached KRW 303B, supporting continued reinvestment of cenobamate-generated profits into R&D.

Financial highlights

• Q3 gross profit was KRW 249.4B, up 35.4% YoY; SG&A was KRW 133.1B, up 16.7% YoY.

• Q3 profit before tax was KRW 95.4B, up 53.5% YoY; net income was KRW 54.3B, down 23.9% YoY.

• Q3 service revenue was KRW 28.9B, including recognition of deferred clinical-activity revenue in Asia and one-time milestone revenue.

Outlook and guidance

• FY XCOPRI sales guidance remained $550M–$580M, with sales expected to reach the upper end.

• FY guidance was maintained at KRW 570B, considering additional Opakalim deal-related expenses.

• FY guidance of KRW 110B was maintained following Q3 DP/API revenue of KRW 5.9B and service revenue of KRW 28.9B.

• Two to three IND submissions are targeted for 2027 across TPD, RPT and CNS small molecules.